Wednesday, July 8, 2026

pharma · Hematologic Malignancies · Solid Tumor, Adult

Farmatek

Farmatek clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP HQ
1994 Founded
14 Employees
PMDA registrant Type
Company details
Status
Public
HQ
Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP
Founded
1994
Employees
14
Programs
26
Drugs
14
Patents
53
Intelligence · Clinical Programs

Farmatek projects

21 ClinicalTrials.gov programs sponsored by Farmatek.

Farmatek has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Biological: ProHema-CB

    Zafatek

    Hematologic Malignancies

    phase 1 mab terminated

    1 trial
  2. FATE-NK100

    Zafatek

    HER2 Positive Gastric Cancer

    phase 1 small molecule completed

    1 trial
  3. FT500

    Zafatek

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial
  4. FT516

    Zafatek

    Acute Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial
  5. FT516

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial
  6. FT522

    Zafatek

    Relapsed/Refractory B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial
  7. FT536

    Zafatek

    Astrocytoma

    phase 1 mab active

    1 trial
  8. FT536

    Zafatek

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial
  9. FT538

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial
  10. FT538

    Zafatek

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial
  11. FT576 (Allogenic CAR NK cells with BCMA expression)

    Zafatek

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial
  12. FT596

    Zafatek

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial
  13. FT596

    Zafatek

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial
  14. FT819

    Zafatek

    Lymphoma, B-Cell

    phase 1 small molecule active

    1 trial
  15. FT819

    Zafatek

    Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)

    phase 1 small molecule active

    1 trial
  16. FT819 in B-cell Mediated Autoimmune Diseases

    Zafatek

    B-cell Mediated Autoimmune Diseases

    phase 1 other active

    1 trial
  17. FT825

    Zafatek

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial
  18. FT836

    Zafatek

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial
  19. Fludarabine

    Zafatek

    Hematologic Malignancies

    phase 1 small molecule completed

    1 trial
  20. ProHema-CB Transplant

    Zafatek

    Metabolic Disorders

    phase 1 mab terminated

    1 trial
  21. Single FT1050 treated UCB unit

    Zafatek

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Farmatek have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.